The Company is a Korea-based company primarily engaged in the bio pharmaceuticals development technology transfer services. The Company mainly provides contract services for the manufacture of bio pharmaceuticals, bio pharmaceuticals development technology transfer services for the manufacture of Chinese hamster ovary (CHO) cell lines and the process of products and gains royalty from the services. The Company also provides reagents which are used for the development of bio pharmaceuticals. In addition the Company is also engaged in the development of bio pharmaceuticals such as Biosimilar EPO, Recombinant Factor VIII and Biosimilar G-CSF. The Company provides its services within domestic market and to overseas markets such as China, India, Mexico, America and Europe. The Company was established on January 29, 2010. The Company share was listed on the Korea Securities Dealers Automated Quotation System ( KOSDAQ ) on March 11, 2016.
Headquarters
4F, 2-Dong, 306, Sinwon-Ro, Yeongtong-Gu, Suwon-Si, Gyeonggi-Do
Suwon; Gyeonggi;
Contact Details: Purchase the Pangen Biotech Inc. report to view the information.
Website: http://www.pangen.com
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service